{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:23:13Z","timestamp":1794208993539,"version":"4.8.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward more frequent readouts of tumor kinetics while preserving quality of life. We present BloodFlow, a new method combining immunomagnetic enrichment of CD138+ circulating plasma cells in peripheral blood (PB) with next-generation flow (NGF), for the detection of PRD below the 2 \u00d7 10\u20136 NGF threshold. BloodFlow detected PRD in 55 of 644 PB samples (8.5%) from 295 patients. Of note, 52.7% PB samples were positive using BloodFlow and negative by NGF. The lowest PRD detected by BloodFlow was 6 \u00d7 10\u20138. Using bone marrow measurable residual disease (MRD) status as the reference, BloodFlow showed positive and negative predictive values of 95.1% and 76.6%, respectively. Detectable PRD during maintenance or observation predicted dismal PFS and overall survival (2-year rates of 0% and 62%, respectively). BloodFlow surpassed NGF in PB and retained independent prognostic value for PFS in multivariate analysis, including transplant eligibility, the revised International Staging System, complete remission, and MRD status. BloodFlow is the first flow cytometry method that detects tumor cells below the 10\u20136 threshold, enabling improved minimally invasive monitoring of patients with MM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2025029234","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T17:07:34Z","timestamp":1747933654000},"page":"964-970","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-162X","authenticated-orcid":false,"given":"Marta","family":"Lasa","sequence":"first","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3074-9229","authenticated-orcid":false,"given":"Carmen","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-1323","authenticated-orcid":false,"given":"Laura","family":"Notarfranchi","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"},{"name":"2Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-3025","authenticated-orcid":false,"given":"Anastasiia","family":"Zherniakova","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"},{"name":"3Russian Research Institute of Hematology and Transfusiology, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-1375","authenticated-orcid":false,"given":"Diego","family":"Alignani","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-2496","authenticated-orcid":false,"given":"Leire","family":"Burgos","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-3008","authenticated-orcid":false,"given":"Maria Jose","family":"Calasanz","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Perez","sequence":"additional","affiliation":[{"name":"4Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, University of Salamanca, CIBERONC CB16\/12\/00233, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Gomez","sequence":"additional","affiliation":[{"name":"5Hospital de Galdakao, Vizcaya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Veronica","family":"Gonzalez de la Calle","sequence":"additional","affiliation":[{"name":"4Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, University of Salamanca, CIBERONC CB16\/12\/00233, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-1318","authenticated-orcid":false,"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"6Hospital Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-7191","authenticated-orcid":false,"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[{"name":"7Instituto de Investigacion Sanitaria Aragon, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-5112","authenticated-orcid":false,"given":"Miguel Angel","family":"Alvarez Rivas","sequence":"additional","affiliation":[{"name":"8Hospital Universitario Reina Sofia, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Clavero","sequence":"additional","affiliation":[{"name":"9Hospital Universitario Virgen De Las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[{"name":"10Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-9133","authenticated-orcid":false,"given":"Ana Pilar","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[{"name":"11Hospital Universitario Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-4839","authenticated-orcid":false,"given":"Sunil","family":"Lakhwani","sequence":"additional","affiliation":[{"name":"12Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-634X","authenticated-orcid":false,"given":"Angela","family":"Iba\u00f1ez","sequence":"additional","affiliation":[{"name":"13Complejo Hospitalario Universitario de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"14Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"15Institut Catal\u00e0 d'Oncologia L'Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"16Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Siewert","sequence":"additional","affiliation":[{"name":"17Research and Development, Miltenyi Biotec BV & Co KG, Bergisch Gladbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"18Department of Medicine and Cytometry Service, Centro de Investigacion del Cancer (IBMCC, USAL\u2013CSIC), University of Salamanca, CIBERONC CB16\/12\/00400, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan-Jose","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"19Hospital Universitario 12 de Octubre, University Complutense, CIBERONC CB16\/12\/00369, CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-3405","authenticated-orcid":false,"given":"Joan","family":"Blade","sequence":"additional","affiliation":[{"name":"16Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"4Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, University of Salamanca, CIBERONC CB16\/12\/00233, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3720","authenticated-orcid":false,"given":"Maria-Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"19Hospital Universitario 12 de Octubre, University Complutense, CIBERONC CB16\/12\/00369, CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"19Hospital Universitario 12 de Octubre, University Complutense, CIBERONC CB16\/12\/00369, CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"4Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, University of Salamanca, CIBERONC CB16\/12\/00233, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, CIBERONC CB16\/12\/00369 and CB16\/12\/00489, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2025082111221050100_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025082111221050100_bib2","article-title":"Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) [abstract]","volume":"144","author":"Goldschmidt","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025082111221050100_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"17","key":"2025082111221050100_bib4","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2025082111221050100_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D\u2019Agostino","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025082111221050100_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"24","key":"2025082111221050100_bib7","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025082111221050100_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025082111221050100_bib9","first-page":"4056","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial","volume":"109","author":"Puig","year":"2024","journal-title":"Haematologica"},{"issue":"23","key":"2025082111221050100_bib10","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"issue":"27","key":"2025082111221050100_bib11","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"JCO"},{"issue":"18","key":"2025082111221050100_bib12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025082111221050100_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2023-179866","article-title":"GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus\/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years (abstract)","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2025082111221050100_bib14","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2025082111221050100_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.21269","article-title":"Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases","volume":"90","author":"Pojero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2025082111221050100_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025082111221050100_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2025082111221050100_bib18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease\u2013based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"JCO"},{"issue":"23","key":"2025082111221050100_bib19","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025082111221050100_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"JCO"},{"issue":"1","key":"2025082111221050100_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"22","key":"2025082111221050100_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2025082111221050100_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2023-186916","article-title":"Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM) (abstract)","volume":"142","author":"Gonzalez","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/964\/2407086\/blood_bld-2025-029234-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/964\/2407086\/blood_bld-2025-029234-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:22:19Z","timestamp":1755789739000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/8\/964\/537392\/Ultrasensitive-detection-of-circulating-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029234","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,21]]},"published":{"date-parts":[[2025,8,21]]}}}